Kopran Limited has filed its Annual Report for the financial year ended March 31, 2026, along with the Notice of its 67th Annual General Meeting (AGM), pursuant to Regulation 34(1) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. The AGM is scheduled to be held on Tuesday, August 18, 2026 at 11.30 a.m. (IST) through Video Conferencing / Other Audio-Visual Means. Established in 1958, the company operates as an integrated pharmaceutical manufacturer supplying Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs) to customers across more than 50 countries.

Financial Performance: Standalone and Consolidated

The company's financial results for FY 2025-26 reflect mixed performance across standalone and consolidated metrics. The following table summarises the key financial highlights as reported in the Annual Report.

On a consolidated basis, the company reported revenue from operations of ₹68,142 lakhs, EBITDA of ₹7,790 lakhs (excluding other income and forex losses), net profit of ₹2,573 lakhs, and net worth of ₹53,028 lakhs. Return on Equity (RoE) stood at 4.9% and Return on Capital Employed (RoCE) at 9.2%, with earnings per share of ₹5.33 and finance costs of ₹1,047 lakhs.

Segment Performance: Formulations and API

The company operates through two business verticals — Formulations (under Kopran Limited) and APIs (through its wholly owned subsidiary Kopran Research Laboratories Limited, or KRLL). The following table presents segment-wise turnover for FY 2025-26.

Within the API segment, revenue of ₹37,335 lakhs was led by Carbapenems (₹18,977 lakhs), Macrolides (₹6,081 lakhs) and Anti-Hypertensives (₹4,580 lakhs). Export sales contributed ₹14,598 lakhs, while domestic sales stood at ₹22,737 lakhs. The formulations segment recorded revenue of ₹29,639 lakhs, with the Penicillin plant contributing ₹17,509 lakhs and the Non-Penicillin plant contributing ₹12,130 lakhs. Region-wise exports were led by South Africa (₹12,574 lakhs) and Africa (₹11,733 lakhs), followed by Southeast Asia, MENA and LATAM markets. The company has commercialised 26 API products and serves regulated and semi-regulated markets across more than 50 countries.

Dividend and Share Capital

The Board of Directors has recommended a final dividend of ₹3.00 (30%) per equity share of face value ₹10 each for FY 2025-26, subject to shareholder approval at the AGM. This is consistent with the dividend declared in the previous year. If approved, the dividend payout would result in a cash outflow of approximately ₹1,448.57 lakh. The paid-up equity share capital as on March 31, 2026 stood at ₹48.28 crores. During the year, the company issued 4,75,000 ESOPs under the 'Kopran Employee Stock Option Plan 2023', with outstanding ESOP grants of 137,700 shares as at year-end. No equity shares were allotted under the ESOP plan during the year.

Key Corporate Developments

Several significant corporate events took place during FY 2025-26 and up to the date of the report:

• Panoli Facility Commencement: The company's brownfield API manufacturing facility at Panoli, Gujarat commenced commercial production on March 31, 2026. The company is pursuing regulatory approvals and customer qualifications across domestic and international markets.
• Scheme of Amalgamation: The Board approved a Scheme of Amalgamation (Merger by Absorption) of Kopran Laboratories Limited (Transferor Company) with Kopran Limited (Transferee Company). Under the scheme, 100 fully paid equity shares of Kopran Limited (face value ₹10 each) will be issued for every 45 equity shares of Kopran Laboratories Limited. BSE and NSE have issued observation letters, and the Hon'ble NCLT, Mumbai Bench, vide its order dated April 09, 2026, has directed the companies to hold meetings of equity shareholders and creditors.
• Board Changes: Mrs. Namrata Somani (DIN: 07095595) was appointed as Director with effect from May 19, 2026. Mr. Susheel Somani resigned with effect from July 29, 2025; Mr. Adarsh Somani resigned with effect from March 17, 2026; and Mr. Siddhan Subramanian and Mrs. Sunita Banerji completed their second terms as Independent Directors on September 17, 2025.
• Capacity Expansion: The company is undertaking expansion of granulation, filling, and packing capacities at its formulations facility, with an estimated capex of ₹25 Crores, to support growing production volumes and CDMO/CMO business.

CSR and Governance

The company was mandated to spend ₹74.46 lacs (2% of average net profits) on Corporate Social Responsibility (CSR) for FY 2025-26. Actual CSR spending during the year amounted to ₹83.53 lacs, resulting in an excess spend of ₹9,06,980 available for set-off in succeeding financial years. The amount available for set-off from the preceding financial year was ₹13.91 lacs. The Board held five meetings during FY 2025-26, and the Secretarial Audit Reports for the year contain no qualifications, reservations, adverse remarks, or disclaimers. The statutory auditors, M/s. Khandelwal Jain & Co., have issued an unqualified opinion on both standalone and consolidated financial statements for FY 2025-26.

AGM and E-Voting Details

The 67th AGM will be conducted via Video Conferencing / OAVM on August 18, 2026. Remote e-voting opens on August 15, 2026 at 09:00 A.M. and closes on August 17, 2026 at 05:00 P.M. The record date for e-voting eligibility is August 11, 2026. Business items include adoption of standalone and consolidated financial statements, declaration of dividend, re-appointment of Mr. Varun Somani (retiring by rotation), and appointment of Mrs. Namrata Somani as Director. The Annual Report is available on the company's website at www.kopran.com/investors .

Kopran Ltd and Kopran Laboratories Ltd have scheduled a hearing for their proposed amalgamation scheme on August 5, 2026. The National Company Law Tribunal (NCLT), Mumbai Bench, will hear the petition for the merger by absorption of Kopran Laboratories Limited with Kopran Limited. The scheme was presented to the Tribunal on June 24, 2026, and subsequently admitted on July 1, 2026.

The filing follows the publication of a public notice in Form CAA-3 to the Central Government and other authorities, adhering to Rule 7 of the Companies (Compromises, Arrangements and Amalgamations) Rules, 2016. The notices were published in Business Standard and Navshakti.

Scheme Details and Petition Status

The petition, numbered Company Scheme Petition No. 90 (MB) of 2026, seeks sanction for the Scheme of Amalgamation involving the transferor company, Kopran Laboratories Limited, and the transferee company, Kopran Limited. Both entities are registered under the Companies Act, 1956, and share the same registered office at Parijat House, Worli, Mumbai.

Stakeholder Participation

Any individual or entity intending to support or oppose the company scheme petition must submit a formal notice of intention. This notice, signed by the person or their advocate, must include the individual's name and address. It should reach the Authorised Representative, M/s PRS Associates, and the Tribunal no later than two days before the hearing date.

Those opposing the petition are required to furnish the grounds of opposition or a copy of their affidavit along with the notice. The Authorised Representative is located at Omega Business Park in Thane, while the Tribunal is situated at Cuffe Parade, Mumbai.

Access to Petition Documents

Copies of the company scheme petition and its annexures are available for inspection. Interested parties may obtain these documents from the Authorised Representative between 11:00 a.m. and 5:00 p.m. on any working day, excluding Saturdays, Sundays, and public holidays. The request must be made at least two days before the hearing date, and prescribed charges apply for obtaining the copies.